Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Epigenetic changes in patients with multiple sclerosis.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Rehabilitation interventions in multiple sclerosis: an overview.
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Multiple sclerosis and progressive resistance training: a systematic review.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Dynamic imaging of individual remyelination profiles in multiple sclerosis.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
First NW patient to receive OHSU/VAMC-invented MS drug
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Ceramide Synthase 6 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis.
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
A practical review of the neuropathology and neuroimaging of multiple sclerosis.
Pages
« first
‹ previous
…
136
137
138
139
140
141
142
143
144
…
next ›
last »